STOCK TITAN
  1. Home
  2. News
  3. APLS

Apellis Pharmaceuticals Inc - APLS STOCK NEWS

Welcome to our dedicated news page for Apellis Pharmaceuticals (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apellis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apellis Pharmaceuticals's position in the market.

News
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will be hosting a conference call on May 7, 2024, to discuss its first quarter 2024 financial results. The call will take place at 8:30 a.m. ET, with options to access via phone or webcast. A replay will be available for 90 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) granted equity awards to a new employee, including 1,215 restricted stock units (RSUs) under the 2020 Inducement Stock Incentive Plan. The RSUs will vest annually, subject to the employee's continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
News
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) will host a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 8, 2024. The webcast will be available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences
News
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) appoints renowned retina specialist Dr. Philip Ferrone as Chief Medical Retina Advisor. Dr. Ferrone's expertise in retina research and patient care will enhance Apellis' efforts in bringing SYFOVRE to GA patients. The company aims to advance its retina pipeline with Dr. Ferrone's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
management
-
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. granted equity awards to a new employee outside of its 2017 Stock Incentive Plan, under the 2020 Inducement Stock Incentive Plan. The employee received 2,795 restricted stock units (RSUs) that will vest annually over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
News
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) reported $397 million in full-year 2023 revenues, with strong sales for SYFOVRE® and EMPAVELI®. The company highlighted the successful launch of SYFOVRE and positive reception for EMPAVELI. They are focused on expanding market reach, advancing their pipeline, and delivering for patients. Financially, Apellis had $351 million in cash as of December 31, 2023, with total revenue of $146.4 million in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
earnings
News
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) will participate in upcoming investor conferences in March 2024, including TD Cowen 44th Annual Healthcare Conference and Raymond James & Associates’ 45th Annual Institutional Investors Conference. The company will host fireside chats and panel discussions, with live webcasts available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
conferences
-
News
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) schedules a conference call to discuss its fourth quarter and full year 2023 financial results on February 27, 2024. Investors can access the call via phone or live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences earnings
-
News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) granted equity awards to 4 new employees outside of the 2017 Stock Incentive Plan. Each employee received 6,265 restricted stock units (RSUs) that will vest annually over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
News
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a negative opinion from the CHMP of the European Medicines Agency on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration. The company plans to seek immediate re-examination of its application. The MAA is based on results from the Phase 3 OAKS and DERBY studies at 24 months, which showed promising treatment effects over time and a well-demonstrated safety profile. However, the negative opinion is disappointing for the millions of Europeans living with GA, a progressive and irreversible form of vision loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
Stock APLS logo
Apellis Pharmaceuticals Inc

Nasdaq:APLS

APLS Rankings

#1093 Ranked by Market Cap
#3412 Ranked by Stock Gains
N/A Ranked by Dividends

APLS Stock Data

6.25B
81.04M
13.24%
95.98%
8.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Waltham

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.